Skip to main content
. 2018 Dec 18;2018:6594169. doi: 10.1155/2018/6594169

Table 1.

Clinicopathological characteristics of HBV-related HCC cases after data quality control.

  NM23       OS   RFS  
  — 1+ 2+ 3+ OR∗ 
(95% CI)		 P value† Total
number		 MST
(months)		 P value‡ HROS ‡ 
(95% CI)		 MRT
(months)		 P value‡ HRRFS ‡ 
(95% CI)
Gender           0.281     0.400     0.651  
 Male 40 241 39 45 1.01
(0.53–1.95)		   365 48   0.93
(0.51–1.69)		 7   1.09
(0.73–1.63)
 Female 3 31 7 2 Ref.   43 82   Ref. 12   Ref.
Age (years)           0.017     0.485     0.718  
 ≤46 20 144 35 24 1.45
(0.97–2.19)		   223 61   0.87
(0.61–1.25)		 7   1.05
(0.80–1.37)
 >46 23 128 11 23 Ref.   185 45   Ref. 11   Ref.
Race           0.159     0.972     0.761  
 Han 32 174 25 26 0.62 
 (0.41–0.95) 		  257 48   0.92
(0.64–1.31)		 7   0.96
(0.73–1.26)
 Minority 11 98 21 21 Ref.   151 50   Ref. 11   Ref.
Preoperation TACE           0.359     0.640     0.592  
 No 30 215 36 40 1.46
(0.88–2.40)		   321 51   0.91
(0.61–1.37)		 10   0.92
(0.67–1.27)
 Yes 13 57 10 7 Ref.   87 44   Ref. 6   Ref.
Postoperation TACE           0.530     0.717     0.416  
 No 26 156 25 22 0.76
(0.88–2.40)		   229 47   0.94
(0.70–1.27)		 7   0.90
(0.68–1.18)
 Yes 17 116 21 25 Ref.   179 76   Ref. 13   Ref.
Smoking status           0.967     0.088     0.053  
 None 14 99 16 17 1.04
(0.51–1.14)		   146 39   1.24
(0.76–2.03)		 5   1.31
(0.98–1.74)
 Ever 29 173 30 30 Ref.   262 61   Ref. 12   Ref.
Drinking status           0.471     0.359     0.443  
 None 16 107 19 24 1.32
(0.88–1.98)		   166 44   0.82
(0.50–1.32)		 6   1.11
(0.84–1.46)
 Ever 27 165 27 23 Ref.   242 51   Ref. 11   Ref.
BMI           0.012     0.480     0.603  
 ≤25 35 206 39 45 1.75 
 (1.05–2.93) 		  325 48   1.03
(0.67–1.59)		 11   0.92
(0.66–1.29)
 >25 8 66 7 2 Ref.   83 63   Ref. 6   Ref.
serum AFP (ng/ml)           0.099     0.101     0.353  
 ≤400 23 143 19 19 0.61 
 (0.40–0.93) 		  204 61   1.00
(0.69–1.44)		 13   0.88
(0.67–1.16)
 >400 16 108 26 26 Ref.   176 41   Ref. 6   Ref.
 NA 4 21 1 2     28            
Child–Pugh           0.509     0.005     0.044  
 A 35 237 37 39 0.88
(0.50–1.54)		   348 51   0.76
(0.48–1.20)		 9   0.66
(0.43–1.01)
 B 8 35 9 8 Ref.   60 31   Ref. 7   Ref.
BCLC stage           0.183     1.35 × 10 -10     0.001  
 A 30 153 26 22 0.66
(0.41–1.05)		   231 101   1.49
(0.40–5.56)		 14   0.57 
 (0.42–0.77)
 B 4 46 10 6 0.92
(0.49–1.71)		   66 39   1.92
(0.46–8.00)		 6   0.66
(0.43–1.03)
 C 9 73 10 19 Ref.   111 27   Ref. 3   Ref.
Number of tumors           0.247     1.95 × 10 -4     0.137  
 Single(n=1) 36 202 32 31 0.63
(0.40–1.00)		   301 58   0.71
(0.39–1.29)		 11   0.80
(0.59–1.09)
 Multiple(n>1) 7 70 14 16 Ref.   107 28   Ref. 5   Ref.
Tumor size (cm)           0.659     0.038     0.175  
 ≤10 37 222 36 36 0.72
(0.44–1.20)		   331 51   0.66
(0.43–1.02)		 12   0.81
(0.58–1.12)
 >10 6 50 10 11 Ref.   77 40   Ref. 4   Ref.
Intrahepatic metastasis           0.325     4.12 × 10 -4     6.03 × 10 -5  
 Absence 24 147 26 19 0.79
(0.53–1.18)		   216 76   1.01
(0.67–1.52)		 13   0.59 
 (0.45–0.78)
 Presence 19 125 20 28 Ref.   192 36   Ref. 4   Ref.
Distant metastasis           0.586#     0.051     0.178  
 Absence 40 249 40 41 0.64
(0.33–1.24)		   370 51   0.38
(0.11–1.34)		 11   0.77
(0.51–1.15)
 Presence 3 23 6 6 Ref.   38 32   Ref. 3   Ref.
Cirrhosis           0.246     0.567     0.923  
 Absence 6 34 3 2 0.54
(0.28–1.04)		   45 48   0.99
(0.59–1.65)		 13   0.98
(0.62–1.54)
 Presence 37 237 43 45 Ref.   362 48   Ref. 7   Ref.
 NA 0 1 0 0     1            
Pathological grade           0.571     0.267     0.105  
 Well 4 17 2 1 0.54
(0.22–1.30)		   24 39   1.07
(0.57–2.02)		 4   1.80
(0.84–3.85)
 Moderately and poorly 35 222 39 36 Ref.   332 47   Ref. 7   Ref.
 NA 4 33 5 10     52            
Regional invasion           0.005     0.407     0.215  
 Absence 38 240 34 34 0.41 
 (0.24–0.71) 		  346 51   0.81
(0.48–1.38)		 11   0.81
(0.58–1.14)
 Presence 5 32 12 13 Ref.   62 40   Ref. 3   Ref.
PVTT           0.162     1.01 × 10 -10     6.75 × 10 -5  
 None 37 225 42 32 0.35
(0.10–1.25)		   336 74   0.10 
 (0.03–0.44) 		12   0.28 
 (0.13–0.60)
 VP1 1 9 0 1 0.24
(0.04–1.42)		   11 28   0.27 
 (0.08–0.99) 		2   0.37
(0.12–1.12)
 VP2 0 11 1 5 0.93
(0.20–4.31)		   17 18   0.53
(0.16–1.74)		 2   0.64
(0.25–1.66)
 VP3 4 23 2 6 0.39
(0.09–1.59)		   35 18   0.36
(0.12–1.10)		 3   0.49
(0.20–1.19)
 VP4 1 4 1 3 Ref.   9 8   Ref. 2   Ref.
Radical resection           0.847     0.025     0.306  
 No 24 147 29 28 1.14
(0.76–1.72)		   228 73   1.01
(0.67–1.52)		 12   0.87
(0.67–1.15)
 Yes 18 114 17 19 Ref.   168 40   Ref. 6   Ref.
 NA 1 11 0 0     12            
Antiviral therapies           0.033     0.005     0.800  
 No 36 174 26 28 0.59 
 (0.39–0.90) 		  264 41   1.88 
 (1.22–2.90) 		6   1.03
(0.79–1.36)
 Yes 7 98 20 19 Ref.   144 NA (>45)   Ref. 13   Ref.
NM23 expression           NA     0.378     0.802  
 Negative 43 - - -     43 47   1.12
(0.54–2.32)		 14   0.88
(0.50–1.53)
 1+ - 272 - -     272 45   1.09
(0.62–1.92)		 7   1.08
(0.72–1.61)
 2+ - - 46 -     46 73   0.68
(0.31–1.46)		 7   0.99
(0.54–1.80)
 3+ - - - 47     47 40   Ref. 11   Ref.

Note. ∗OR for univariate ordinal logistic regression analysis; when the P–value of the OR in the test of parallel lines was less than 0.05, multivariate logistic regression analysis was used but is not shown in the table. †P–value for Chi-square test or Fisher's exact test. ‡HR and P–values are for univariate survival analysis. PVTT was classified using the radiographic results of enhanced computed tomography scanning as follows: vp1=PVTT in distal to second-order portal branches; vp2=PVTT in second–order portal branches; vp3=PVTT in first–order branches; and vp4=PVTT in the main trunk [15].

Abbreviations. GWAS: genome–wide association study; OR: odds ratio; 95% CI: 95% confidence intervals; MST: median survival time; MRT: median recurrence time; HR, hazard ratio; Ref.: reference; NA: not applicable; TACE: transcatheter arterial chemoembolization; BMI: body mass index; AFP: alpha–fetoprotein; BCLC: Barcelona Clinic Liver Cancer; PVTT: portal vein tumor thrombus.